Clinical Trial Update: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating HIV clade C DNA vaccine and MF59- or AS01B-adjuvanted clade C Env protein vaccines in healthy, HIV-uninfected adults; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• AS01B-adjuvanted clade C Env protein vaccine
• HIV clade C DNA vaccine
• MF59-adjuvanted clade C Env protein vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-09-16